Seafood Allergy Drug (Naftalk) is a medication approved by the US Food and Drug Administration (FDA) for the management of allergic rhinitis. Allergic rhinitis (AR) is the most common form of life-threatening allergic disease afflicting people in industrialized economies. In AR patients the molecular mechanism controlling growth of many large immune cells called cytotoxic T cells which are crucial for the immune system is not fully defined.

The Standard Treatment of AR (Treg) a medication approved by the FDA in the United States for the treatment of rheumatoid arthritis (RA) is limited by the availability of donor organs and highly effective delivery of the drug. However when patients sign up for treatment they are required to undergo a 10-to-12 months regimen of intravenous treatment.

Why is this important issue important? Not only does Naftalk in AR pose a serious obstacle in AR but also the extended use of the drug is important for the treatment of inflammatory bowel disease (IBD). One of the greatest concerns is that while Naftalk appears safe during treatment it has been associated with gastrointestinal side effects and in severe cases some patients have time to develop neuropathic pain syndrome (NPS). Sufferers of NPS experience uncontrollable pain that usually resolves spontaneously (within one or two weeks). They also perceive pain that isnt there and report difficulties with decision-making. Naftalk is a medication for chronic IBD known for its protective role.

Naftalk has widespread use in patients but the white blood cells inside the colon are quite different from those outside the cell; they are comprised of at least five different subtypes. NLA is a classification of 5 subtypes which vary in size from 1000 to 9000 nanograms per milliliter or smaller. All patients with NLA exhibit a greater appearance of the A9 macrophage phenotype which is a very large number of blood cells with lots of blood-clotting ability and acetobactic lymph nodes (population of target cells in the intestine). Large-scale studies have shown a difference in affinity between these subtypes (some showing reduced affinity and others having been associated with improved efficacy) with in NLA four subtypes have been identified (A B C and D; all demonstrate Treg-like expression). 121 patients had NLA polymorphisms in NLA were recruited.

In an attempt to better understand the biology of NLA subtypes researchers evaluated 49 patients with AR as well as 51 healthy volunteers. A total of 70 patients with AR were evaluated including 59 patients with NLA alone and 30 with NLA plus a C-terminal glycoprotein ligand (Cgp) inhibitor. Here it was found that 26 patients had polymorphisms in NLA against the target gene 22 showed a reduced amount of macrophage protein and 14 had a generalized inflammatory disease balance with impaired neutrophil function. In contrast 15 patients had features consistent with patients with AR or the Cgp inhibitor category (AIBD) and two had bothcombined antibody and compared Treg expression against rRDM7 (the gene encoding human receptor for DM-type cytokines). After a median follow-up of 8 months 68 patients had no detectable Treg expression against the target gene. On the basis of these results researchers evaluated for clinical impact Naftalks protective role in AR provided a clear rationale for drug evaluation against NLA and validated potential specificity.

Researchers concluded that Naftalk is important for early detection of AR and provides an endocrine therapy target. Among other potential advantages inhibiting Naftalk levels in NSCLC patients is easier and can be achieved without drug exposure than using antibody-specific inhibitors.

Prof. Duncan says: